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Available online xxxxBackground: Abnormal 12 lead electrocardiogram (ECG) findings and proposing its ability for enhanced risk pre-
diction,majority of the studies have been carried outwith elderly populationswith prior cardiovascular diseases.
This study aims to denote the association of sudden cardiac death (SCD) and various abnormal ECGmorphologies
using middle-aged population without a known cardiac disease.
Methods: In total, 9511 middle-aged subjects (mean age 42 ± 8.2 years, 52% males) without a known cardiac
disease were included in this study. Risk for SCD was assessed after 10 and 30-years of follow-up.
Results: Abnormal ECG was present in 16.3% (N = 1548) of subjects. The incidence of SCD was distinctly higher
among those with any ECG abnormality in 10 and 30-year follow-ups (1.7/1000 years vs. 0.6/1000 years, P b
0.001; 3.4/1000 years vs. 1.9/1000 years, P b 0.001). At 10-year point, competing risk multivariate regression
model showed HR of 1.62 (95% CI 1.0–2.6, P = 0.05) for SCD in subjects with abnormal ECG. QRS duration
≥ 110 ms, QRST-angle N 100°, left ventricular hypertrophy, and T-wave inversions were the most significant in-
dependent ECG riskmarkers for 10-year SCD predictionwith up to 3-fold risk for SCD. Thosewith ECG abnormal-
ities had a 1.3-fold risk (95% CI 1.07–1.57, P = 0.007) for SCD in 30-year follow-up, whereas QRST-angle N 100°,
LVH, ER ≥ 0.1mVand ≥0.2mVwere the strongest individual predictors. Subjectswithmultiple ECG abnormalities
had up to 6.6-fold risk for SCD (P b 0.001).
Conclusion: Several ECG abnormalities are associated with the occurrence of early and late SCD events in the
middle-age subjects without known history of cardiac disease.






The annual incidence of sudden cardiac death (SCD) in the United
States is estimated to be as high as 450,000 cases (which accounts ap-
proximately 63% of all cardiac deaths) and the majority of SCD events
occur in asymptomatic subjects considered to be at low- or intermedi-
ate risk for SCD [1–3]. Thus, improvements in risk stratification areoundation, Helsinki, Finland; The
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bility and freedom from bias of
in this study.
B.V. This is an open access article uurgently required and as SCD is primarily a result of electrical distur-
bance of the normal cardiac rhythm, 12 lead electrocardiogram (ECG)
is still an attractive non-invasive tool beyond clinical factors. In ideal
circumstances, health care professionals would have simple tools for
overall SCD risk evaluation combining genetic and demographic infor-
mation to clinical data, such as12 lead electrocardiogram (ECG) and
echocardiography.
Risk predictionmodels for SCD and individual ECG abnormalities as-
sociated with SCD have been described earlier in numerous papers, but
they have mainly been carried out in elderly populations and/or with
patients with cardiovascular disease [4–10]. We aimed to clarify the
prognostic significance of abnormal ECG findings in middle-aged sub-
jects without known cardiac disease.
2. Methods
The Finnish Mobile Health Examination Survey, a large nationwide
study was carried out in Finland between 1966 and 1972 [11]. As ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of subjects at baseline.
Normal ECG Any ECG abnormality P value
(N = 7963) (N = 1548)
Males (%)a 50.8 63.0 b0.001
Age (years)b 42.8 ± 8.1 44.5 ± 8.6 b0.001
Current smoker (%)c 33.9 38.2 0.001
Diabetes (%)c 1.3 1.9 0.369
Cholesterol (mmol/l)c 6.46 ± 1.3 6.49 ± 1.3 0.695
BMI (kg/m2)c 25.8 ± 3.7 25.2 ± 3.6 0.001
Systolic blood pressure (mmHg)c 135 ± 19 144 ± 23 b0.001
a Adjusted for age.
b Adjusted for gender.
c Adjusted for age and gender.
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formed using 12 different geographical regions in Finland. Men and
women aged 31 to 61 were invited to participate (N = 12,310, partici-
pation rate 89%). Age, body mass index (BMI), cholesterol, blood pres-
sure, 12 lead ECG as well as health questionnaire concerning current
and prior health status (smoking, medications used, pain, chronic dis-
eases etc.) were obtained as described earlier [12]. Overall, 10,904
ECGs were available for this study. Study was carried out following eth-
ical guidelines and principals of the Declaration of Helsinki.
As this study focused on abnormal ECGfindings in subjectswithout a
known cardiac disease, exclusion was based on reported information
and certain ECG findings. The exclusion criteria were identical to our
previous study [12]. In brief, unreadable or missing ECGs, patients
with atrial fibrillation, Wolf-Parkinsonson-White ECG pattern or pace-
maker rhythm were excluded. Subject with a known cardiac disease
(N = 895, information based on self-reported history of cardiac symp-
toms ormedication, national registries using International Classification
of Diseases (ICD) as well as the National Drug Reimbursement Registry
maintained by the Finnish National Social Insurance Institution), symp-
toms of cardiac disease (N = 245) and those using cardiac medication
(N=253)were discounted from the analysis. The total of 9511 subjects
(77.3% of the original population) were included in this study.
All participants had 12 lead ECG recordings at baseline (paper speed
50 mm/s). Abnormal ECG findings were defined as: 1) QRS duration
over 110 ms (interpreted from leads II or V5); 2) QRST angle over
100°; 3) QTc interval over 440 ms/460 ms (men/women); 4) left ven-
tricular hypertrophy ([LVH] defined by Sokolow-Lyon criteria or
Romhilt-Estes point score ≥ 5); 5) early repolarization (ER ≥ 0,1 mV
and ER ≥ 0,2 mV) in inferior/lateral leads with descending or horizontal
ST-segment; 6) T-wave inversions (≥1.0 mm deep in other leads than
aVR, Minnesota codes 5.1 to 5.2).
The death certificate diagnoses, assigned by the physician responsi-
ble for the care at the time of death, was obtained from the Causes of
Death Registry which is maintained by the Statistics of Finland. These
certificates were manually studied by a committee of experienced car-
diologists unaware of the data analysis. Events of SCD were defined as
arrhythmic according to the Cardiac Arrhythmia Pilot Study, criteriaTable 2
Competing risk regression model and hazard ratios (HR), 10-year follow-up.
Univariate HR
Normal ECG (N = 7963) 1.0
Any ECG abnormality (N = 1548, 16.3%) 2.86 (1.77–4.62)
QRS duration N 110 ms (N = 110, 1.2%) 6.44 (2.59–16.00)
QTc (N = 534, 5.6%) 2.68 (1.38–5.22)
QRST-angle N 100° (N = 125, 1.3%) 5.61 (2.26–13.90)
LVH (N = 395, 4.2%) 5.07 (2.78–9.23)
ER ≥ 0,1 mV (N = 351, 3.7%) 1.12 (0.35–3.55)
ER ≥ 0,2 mV (N = 40, 0,4%) 0.00 (0–0)
T-wave inversion (N = 284, 3,0%) 4.05 (1.94–8.45)
a Adjusted for age, gender, systolic blood pressure, diabetes, BMI and cholesterol. ECG = ele
pertrophy, QTc = heart rate corrected QT interval. HRs for ER N 0.2 mV were not possible to anbeing described earlier in detail [13,14]. The primary endpoint was
SCD during a follow-up of 30 years and secondary endpoint was SCD
in 10 years of follow-up.
Continuous variables are presented as means ± standard deviation
(SD). We used the Fine and Gray competing risk model for assessment
of adjusted and unadjusted hazard ratios (HR) and 95% confidence in-
tervals (95% CI). Adjustments in multivariate model included age,
gender, systolic bloodpressure, smoking, bodymass index (BMI), diabe-
tes, blood cholesterol and smoking. In baseline, diabetes was screened
with a one-hour glucose tolerance test and urine sample, if not diag-
nosed earlier. For further assessment of risk prediction value, we used
the Integrated Discrimination Increment (IDI) analysis and C-statistics.
The log-rank test was used in our Kaplan-Meier graphs. Statistical anal-
ysis was performed using Statistical Package for Social Sciences (SPSS,
version 24, IBM SPSS Statistics, Armonk, NY) and R Statistics (3.4.1,
The R Foundation for Statistical Computing, Vienna, Austria). Two-
sided P-values b 0.05 were considered significant.
3. Results
The demographic comparison of the groups is presented in Table 1.
After exclusions, a total of 9511 subjects included in the analyses. A
total of 1548 had at least one ECG abnormality present (test group).
A total of 73 subjects suffered SCD in 10-year follow-up and 641 in
30-year follow-up. The incidence of SCD in the test group at 10-year
point was 1.7/1000 years compared to 0.6/1000 years in the reference
group. Incidences were 3.4/1000 years and 1.9/1000 years during the
30-year follow-up, respectively. The negative predictive value of normal
ECG in 10-year follow-up was 99.4%.
3.1. 10-year analysis
The competing risk regression model (adjusted and unadjusted) for
10-year events is presented in Table 2. In the 10-year analysis the
univariate yielded a 2.86 HR (95% CI 1.77–4.62, P b 0.001) and the mul-
tivariate 1.62 (1.00–2.62, P = 0.052) for those with abnormal ECG.
The strongest predictors of SCD in multivariate analysis were QRS
≥ 110 ms (HR 3.09, 95% CI 1.27–7.52, P = 0.013), QRST-angle N 100°
(HR 3.4, 95% CI 1.37–8.44, P = 0.009), LVH (HR 2.67, 95% CI 1.42–5.01,
P = 0.002) and T-wave inversions (HR 2.98, 95% CI 1.30–6.79 P =
0.010). Subjects with ER ≥0.2 mV had no SCD events during this period,
furthermore prevalence being only 40. The survival curves for SCD
events is presented in Fig. 1. For predicting non-sudden cardiac death,
abnormal ECG did not increase the risk in multivariate adjusted regres-
sion model (HR 1.10, 95% CI 0.87–1.38, P = 0.440).
To determine the risk prediction value of abnormal ECG further, we
used the C-index and IDI analysis. Original model included known risk
factors of cardiac disease: age, gender, systolic blood pressure, diabetes
and smoking. After adding abnormal ECG variable to the original model,
the C-index showed no significant improvement in risk prediction for
SCD, whereas the IDI analysis showed aminor improvement in risk pre-
diction (IDI 0.0033, P = 0.032).P-value Multivariate HRa P-value
1.0 1.0 1.0
b0.001 1.62 (1.00–2.62) 0.052
b0.001 3.09 (1.27–7.52) 0.013
0.004 1.26 (0.64–2.48) 0.500
b0.001 3.40 (1.37–8.44) 0.009
b0.001 2.67 (1.42–5.01) 0.002
0.850 0.86 (0.27–2.72) 0.800
N/A 0.00 (0–0) N/A
b0.001 2.98 (1.30–6.79) 0.010
ctrocardiogram, ER = early repolarization, HR = hazard ratio, LVH = left ventricular hy-
alyze as no events occurred in this group during the 10-year follow-up.
Fig. 1. Mortality rates in subject with and without ECG abnormalities for sudden cardiac
death.
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The results of competing risk regressionmodel for 30-year follow-up
is presented in Table 3. In the univariate model, subjects with ECG ab-
normalities had a risk of 1.67 (95% CI 1.39–2.00, P b 0.001) compared
to the reference group. In multivariate analysis the risk of SCD was
1.30 (95% CI 1.07–1.57, P = 0.007). In effort to evaluate the predictive
value of individual abnormal ECG findings, QRST-angle N 100° (HR
1.79, 95% CI 1.08–2.95, P = 0.023), LVH (HR 1.52, 95% CI 1.12–2.05,
P = 0.007), ER ≥ 0,1 mV (HR 1.60, 95% CI 1.15–2.21, P = 0.005)
and ER ≥ 0,2 mV (HR 2.60, 95% CI 1.28–5.29, P = 0.009) showed signif-
icant association to SCD in 30-year follow-up. Abnormal ECG did not
predict non-sudden cardiac death in multivariate analysis (HR 0.99,
95% CI 0.91–1.08, P = 0.820). The C-index for SCD showed a minor,
but not significant improvement in risk prediction (original model
0.708; model with abnormal ECG 0.710, P= 0.583). IDI analysis yielded
a minor improvement in risk prediction (IDI 0.0027, P = 0.003).3.3. Cumulative risk of combined ECG abnormalities
The number of ECG abnormalities detected had an impact on the
resulting risk for SCD, as shown in Fig. 2. The risk for SCD was 3-fold
for both 10-year and 30-year follow-up when two or more ECG abnor-
malities were observed (Table 4). Comparing those with normal ECGTable 3
Competing risk regression model, 30-year follow-up.
Univariate
Normal ECG (N = 7963) 1.0
Any ECG abnormality (N = 1548, 16.3%) 1.67 (1.39–2.00)
QRS duration N 110 ms (N = 110, 1.2%) 2.20 (1.30–3.72)
QTc (N = 534, 5.6%) 1.56 (1.18–2.07)
QRS-T angle N 100° (N = 125, 1.3%) 2.33 (1.45–3.77)
LVH (N = 395, 4.2%) 2.01 (1.50–2.71)
ER ≥ 0,1 mV (N = 351, 3.7%) 1.81 (1.31–2.49)
ER ≥ 2 mV (N = 40, 0,4%) 3.29 (1.63–6.67)
T-wave inversion (N = 284, 3,0%) 1.41 (0.948–2.08)
a Multivariate model included age, gender, systolic blood pressure, diabetes, BMI and choles
ventricular hypertrophy, QTc = heart rate corrected QT interval. Adjusted for age, gender, systand subjects with ≥2 ECG abnormalities, the C-index showed a minor
but not significant improvement for SCD risk prediction (10-year analy-
sis 0.821 vs 0.823, P = 0.662; 30-year analysis 0.755 vs 0.758, P =
0.153, respectively).
In addition, when prolonged QRS complex (QRSd ≥ 110 ms) was ac-
companied by any of the measured ECG abnormalities (N = 110), the
risk for SCD was 6.6-fold (95% CI: 2.6–16.3; P b 0.001) in the 10-year
follow-up and 2.9-fold (95% CI: 1.7–5.0) in the 30-year follow-up.
After adjustments for clinical covariates these risks decreased to 2.9-
fold (95% CI: 1.2–7.4; P = 0.022) and 1.8-fold (95% CI: 1.1–3.1; P =
0.029), for 10-year and 30-year follow-ups, respectively.
4. Discussion
In this study setting of middle-aged subjects without a known car-
diac disease, several ECG abnormalities were found to possess predic-
tive value for SCD events. The predictive power of various ECG
markers was variable during 10-year and 30-year follow-up periods.
In summary, results suggest abnormal QRST-angle, LVH and ER ≥
0.2mV having the highest predictive value for SCD events, and cumula-
tive impact of multiple ECG risk variants markedly improves the risk
prediction of SCD events in subjects with no history of cardiac disease.
The IDI analysis showed aminor enhance in risk prediction with abnor-
mal ECG for SCD. However, abnormal ECG did not improve the risk pre-
diction model in C-statistics, probably due to strong variables in the
original model (age, gender, BMI, high blood pressure, cholesterol, dia-
betes, smoking).
Sudden cardiac death is considered as a multifactorial event and it is
vital to understand the various causes and mechanisms known to in-
crease the risk of SCD [2,15,16]. Majority (80%) of SCD events occur in
elderly patients with coronary arterial abnormalities, and minority of
SCD cases derive from to cardiomyopathies, valvular/congenital heart
diseases and electrophysiological abnormalities. However, stroke, aortic
rupture, intoxication and pulmonary embolism are also known triggers
of SCD. In 2004, The Framingham Heart Study examined the current
trend of SCD, if the mortality rates were in line with notably decreased
number of fatal coronary heart disease (CHD) events [17]. They con-
cluded that the incidence of SCD events has decreased by 49% during
the past 5 decades. This confirms the importance of primary and
secondary intervention of CHD to reduce the incidence of SCD. This phe-
nomenon is also seen in the incidence rates of SCD according to age. The
age-related incidence of SCD is demonstrated to form a peak among
children under the age of five, remaining low for the age groups of
5 to 44 years, and increasing rapidly from the age of 45 indicating the
importance of CHD prevention in effort to decrease SCD events [2].
4.1. ECG risk markers for SCD
In a recent study, ECG risk variants were evaluated in the context of
left ventricular ejection fraction (LVEF) for better prediction of future
SCD events [18]. They utilized data from the community-based OregonP-value Multivariatea P-value
1.0 1.0 1.0
b0.001 1.30 (1.07–1.57) 0.007
0.003 1.57 (0.91–2.72) 0.110
0.002 1.06 (0.79–1.43) 0.670
0.001 1.79 (1.08–2.95) 0.0230
b0.001 1.52 (1.12–2.05) 0.007
b0.001 1.60 (1.15–2.21) 0.005
0.001 2.60 (1.28–5.29) 0.009
0.090 1.33 (0.88–2.02) 0.170
terol. ECG= electrocardiogram, ER= early repolarization, HR= hazard ratio, LVH= left
olic blood pressure, diabetes, BMI and cholesterol.
Fig. 2. Cumulative effect of abnormal ECG findings for sudden cardiac death.
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trols studying a total of 8 abnormalities on ECG. Results indicated
progressively greater risk of SCD in subject with multiple ECG abnor-
malities combinedwith preserved (N35%) LVEF. Subjectswith ≥4 abnor-
mal ECG variants had over a 20-fold risk (95% CI 9.4–47.7, P b 0.001)
for SCD. The results suggested that the cumulative effect of ECG
riskmarkerswas a strongpredictor of future SCD events among subjects
with LVEF over 35%. This can be regarded as a marked finding since
we lack proper clinical tools and knowledge for decent SCD prediction.
From this perspective, our results are parallel for showing remarked
elevation of SCD risk for those with multiple risk variants on 12 lead
ECG.
In case of prolonged QRS duration (QRSd) and intraventricular con-
duction delay (IVCD), the consensus as usable risk variable for SCD is not
uniform [6,10,19,20]. Aro et al. in 2011 performed a general population
study and concluded QRSd ≥ 110 ms and IVCD as a significant risk
marker for SCD with 2- and 3-fold risks, respectively [6]. Our results
suggested QRS duration as a risk factor for SCD in 10-year analysis, how-
ever no value in risk prediction was found in longer follow-up period.
Nonetheless, the segregation between QRSd/IVCD being independent
markers for SCD or just amanifestation ofmore proceeded cardiovascu-
lar disease remains debatable.
The total electrical activity of the heart including depolarization and
repolarization measured by QT interval is often corrected with Bazett's
formula. Patients with long QT syndrome (LQTS), composed of a
heterogenic group of patients with genetic variability affecting ion
channels of the myocardial cells are known to be at high risk for SCD
events [21–23]. However, a clear majority of subjects with prolongedTable 4
Association between the number of ECG abnormalities and risk for sudden cardiac death.
Number of ECG abnormalities Number of SCDs/subjects at risk Un
10-year follow-up
1 ECG abnormality 16/1313 2.1
≥2 ECG abnormalities 10/186 7.6
30-year follow-up
1 ECG abnormality 87/1313 1.5
≥2 ECG abnormalities 37/186 4.5
a Adjusted for age, gender, systolic blood pressure, diabetes, BMI and cholesterol. ECG = eleQTc do not have these genetic abnormalities and this abnormal ECG
finding is regarded as idiopathic or drug induced. Some studies suggest
QTc as a significant risk predictor for SCD in both CAD and general pop-
ulation samples with 3 to 5-fold risk [24–26]. Algra et al. in 1991studied
QTc as an independent risk factor for SCD in patients with andwithout a
history of cardiac dysfunction [26]. They utilized 24-h ambulatory elec-
trocardiographs and subject were followed up to 2 years. In subjects
without intraventricular conduction defect, QTc N 440 ms was associ-
ated to SCD with a 2.3-fold risk (95% CI 1.4–3.9) compared to those
with QTc b 440 ms. Prolonged QTc did not increase the risk of SCD in
subjects with cardiac dysfunction. In our study setting of middle-aged
patients with no history of cardiac disease, prolonged QTc did not
show significantly elevated risk for SCD in neither 30-year nor 10-year
follow-up periods. As the results remains controversial, the overall risk
prediction value of prolonged QTc for SCD needs further scientific veri-
fication [20].
A decade ago, the pattern of early repolarization (ER) on 12 lead ECG
was considered as a benign variant. However, Haïssaguerre et al. in
2008 reported that subjects with ER had a significantly higher risk of
sudden cardiac arrest and idiopathic ventricular fibrillation than those
without this ECG pattern, even without clinical evidence of structural
heart disease or evident abnormalities on resting ECG [9]. This study
was followed by Tikkanen et al. in 2009, suggesting J-point elevation
in inferior leads as a significant predictor of SCD, especially in case of
ER ≥ 0.2 mV [14]. Recently, this knowledge has been strengthened and
ER needs to be considered as a noteworthy risk marker for SCD events
[27]. Our study results are in line with previous conclusions. Early repo-
larization seems to have value in predicting SCD. However, more high
quality clinical trials are needed in effort to discover practical and
cost-effective means to recognize and treat these patients.
The spatial and frontal QRS-T angle calculated by using
vectorcardiography of depolarization and repolarization has been stud-
ied for decades and this field research has reemerged in recent years as
it has been associated with increased risk of cardiac death and SCD [28].
The definition of an abnormal QRS-T angle varies (from 100° to 135°)
depending on the study [28–31]. In selected studies using large general
populations, QRS-T anglewas regarded as a significant risk factor for ad-
verse cardiac events. The hazard ratio for cardiac mortality varied from
1.9 to 5.2, and the risk for SCD from 2.3 to 5.6. Our study yielded parallel
results. The significance was notable in 10-year risk prediction. In addi-
tion, T-wave inversions are suggested as isolated risk factor for SCD [32].
Thiswas also noted in our study. T-wave inversions showed a 3-fold risk
in 10-year period but had no significance in 30-year follow-up.
Left ventricular hypertrophy on ECG is regarded as a potential
trigger of ventricular arrhythmias and therefore regarded as a risk
marker for SCD events [33]. This has been established especially
among patient with hypertension induced hypertrophy [34]. This in-
creased risk was noted in this setting of middle-aged subjects with
no history of cardiac disease, being one of the strongest individual
predictors for SCD.
Currently, we obviously lack decent tools for SCD prediction. As re-
cent studies have implied, a 12 lead ECG provides evident benefits for
this field of research. Wide availability, simple interpretation and goodivariate P value Multivariatea P value
0 (1.19–3.69) 0.011 1.29 (0.72–2.30) 0.393
2 (3.85–15.09) b0.001 3.22 (1.57–6.62) 0.001
5 (1.23–1.96) b0.001 1.12 (0.89–1.43) 0.334
7 (3.26–6.41) b0.001 2.97 (2.09–4.20) b0.001
ctrocardiogram.
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More prospective studies are needed to validate novel risk models for
SCD prediction. From electrocardiographic point of view, future studies
should focus on both individual and combined ECG risk variants along-
side with other clinical factors.
4.2. Study limitations
As retrospective study, a few limitations are obvious concerning this
study. For identifying subjectswith andwithout cardiac disease, thedef-
inition was based on self-reported information. This information was
obtained by using a questionnaire including data of used medications,
symptoms (angina pectoris for example), and was performed by a
trained nurse. At that time of pre-digitalization and lacking electronic
patient report regimes, this was regarded as the most reliable method
for obtaining a large amount of data. We cannot out rule the possibility
of a silent cardiac disease developing during the 30-year follow-up.
After the time of baseline study in 1960s' to 1970s', the practice of
medicine has gone throw major changes. As the general knowledge of
diseases, symptoms and risk prevention is being brought to public
awareness via internet and public channels, and this information is
added to the constantly growing prosperity and well-being, it is appar-
ent that the utilization of health care has increased substantially. This
general knowledge combined with more advanced and novel clinical
tools have led to early diagnosis and/or intervention to prevent adverse
events. Therefore, comparing the past and the present era, the risk pro-
files are not completely in line for the risk of SCD. More studies are
needed using populations of the present time, rather with various eth-
nic backgrounds.
4.3. Future directions of SCD prevention
As for risk prediction for SCD events, the current consensus and un-
derstanding relies on prevention/treating/diagnostics of known risk fac-
tors, such as CHD, congenital heart/valvular diseases and LQTS.
Improved knowledge of drugs with potency of QT prolongation edu-
cates clinical practitioners for reasonable evaluation of medication to
prevent redundant SCD events. Since the all mechanisms of SCD are
not completely understood, the risk evaluation of those with no clinical
symptoms or known risk factors for SCD still remains challenging and
more research is needed. As for future innovation in general practice
with constantly increasing knowledge for SCD riskmarkers, considering
cost-effectiveness and availability, the development of automated ECG
analysis could involve more advanced algorithms to detect those sub-
jects with multiple known risk factors. This initial risk assessment
could lead to further diagnostic inspection with traditional methods
such as echocardiogram, magnetic resonance imaging and Holter mon-
itoring. For example, patient with numerous risk variables on ECG com-
binedwith low (b35%) left ventricular ejection fraction (LVEF) on ECHO
imaging, could benefit primary prevention with ICD therapy, thus im-
proving the “number needed to treat” rate compared to risk assessment
using only LVEF values [35]. As genetic testing has grown dramatically
over the past decades with decreasing expense, this field of research
probably improves the future risk assessment for SCD.
5. Conclusion
Electrocardiogram is a valuable and inexpensive tool for predicting
SCD events in middle-aged subjects with no history of cardiac disease.
There seems to be an obvious correlation between the risk of SCD and
the number of observed abnormal ECG findings. The prediction of SCD
should include multiple clinical risk factors (age, gender, diabetes,
smoking, blood pressure, cardiac function) in addition to observed
ECG abnormalities. Future clinical studies on predictive value of ECG
should be performed using both traditional and novel statistical
methods. Studies providing more exact information about the high-risk combination of ECG variants could offer medical professionals
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